Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
Status:
Not yet recruiting
Trial end date:
2025-05-15
Target enrollment:
Participant gender:
Summary
This is a multi-center, longitudinal study which will characterize the gene expression
profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic
dermatitis (AD) and will determine changes in these expression patterns and endotypes in
response to standard-of-care treatment. Participants will complete up to nine study visits
with assessment of topical steroid response and dupilumab response (if uncontrolled with
topical steroids). Skin samples will be collected at all study visits to determine the gene
expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD
disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and
microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease.
Non-AD participants will serve as a control population.
The primary objective of this study is to determine if the type 2-high non-lesional skin
(skin tape) endotype is associated with current mild versus moderate-severe AD disease.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)